Trial Profile
Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms CELIM
- 15 Apr 2022 Results Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3) assessing survival after secondary liver resection in metastatic colorectal cancerpublished in the International Journal of Cancer
- 04 Jun 2019 Results of a comparative analysis assessing survival after secondary liver resection in metastatic colorectal cancer in LICC, FIRE-3 and CELIM, presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2013 Overall and progression-free survival results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.